Document is current
Any future updates will be listed below
-
Authors
Wang, Xuan https://orcid.org/0000-0002-4160-0761
Tian, Hui
Chi, Zhihong
Si, Lu https://orcid.org/0000-0002-2123-9761
Sheng, Xinan https://orcid.org/0000-0001-9359-0975
Hu, Han https://orcid.org/0000-0002-8188-6143
Gu, Xiangyong
Li, Siming
Li, Caili
Lian, Bin https://orcid.org/0000-0003-0090-1290
Zhou, Li https://orcid.org/0000-0002-9331-0600
Mao, Lili
Tang, Bixia https://orcid.org/0000-0002-3458-461X
Yan, Xieqiao
Wei, Xiaoting
Li, Juan
Liu, Binlei
Guo, Jun
Kong, Yan
Cui, Chuanliang https://orcid.org/0000-0001-6455-0843
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct04386967 at ClinicalTrials.govnct05868707 at ClinicalTrials.govDocuments that mention this clinical trial
Oncolytic virus OH2 extends survival in patients with PD-1 pretreated melanoma: phase Ia/Ib trial results and biomarker insights
https://doi.org/10.1136/jitc-2024-010662
nct04386967 at ClinicalTrials.govDocuments that mention this clinical trial
Oncolytic virus OH2 extends survival in patients with PD-1 pretreated melanoma: phase Ia/Ib trial results and biomarker insights
https://doi.org/10.1136/jitc-2024-010662
nct03866525 at ClinicalTrials.govDocuments that mention this clinical trial
Oncolytic virus OH2 extends survival in patients with PD-1 pretreated melanoma: phase Ia/Ib trial results and biomarker insights
https://doi.org/10.1136/jitc-2024-010662
nct05868707 at ClinicalTrials.govDocuments that mention this clinical trial
Oncolytic virus OH2 extends survival in patients with PD-1 pretreated melanoma: phase Ia/Ib trial results and biomarker insights
https://doi.org/10.1136/jitc-2024-010662
nct05868707 at ClinicalTrials.govDocuments that mention this clinical trial
Oncolytic virus OH2 extends survival in patients with PD-1 pretreated melanoma: phase Ia/Ib trial results and biomarker insights
https://doi.org/10.1136/jitc-2024-010662
Documents that mention this clinical trial
Oncolytic virus OH2 extends survival in patients with PD-1 pretreated melanoma: phase Ia/Ib trial results and biomarker insights
https://doi.org/10.1136/jitc-2024-010662
-
Funding
Funding for this research was provided by:
Clinical Medicine Plus X-Young Scholars Project of Peking University (PKU2022LCXQ030)
Beijing Municipal Administration of Hospitals Incubating Program (PX2024040)
- License Information
